partnershipC4X Discovery Holdings inks $402m deal with AstraZenecaLatest NewsC4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m. Read more 28 November 2022 https://european-biotechnology.com/wp-content/uploads/2024/04/AstraZeneca_headquarters.jpg 1124 2000 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2022-11-28 12:59:042024-07-16 12:17:18C4X Discovery Holdings inks $402m deal with AstraZeneca